What the Study Found (In Plain English)
Published in Future oncology (London, England) (2021), this phase iii randomized trial evaluating human clinical outcomes investigated: Standard-of-care, first-line therapy for patients with advanced HER2+ gastric/gastroesophageal junction adenocarcinoma is chemotherapy plus trastuzumab, a monoclonal antibody (mAb) targeting HER2. Key clinical takeaway: Primary end points include objective response rate, overall survival and safety/tolerability. Clinical trial registration: NCT04082364
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Future oncology (London, England), 2021-04-15; Phase III Randomized Trial; Rigor 82/100): Primary end points include objective response rate, overall survival and safety/tolerability. Clinical trial registration: NCT04082364
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.